Collection of Circulating Biomarkers in Pancreatic Cancer

Recruiting

• Conditions: Pancreas Cancer

• Registration Number: NCT05743049
• Lead Sponsor: Abramson Cancer Center at Penn Medicine

Brief Summary

This protocol will involve collection of blood samples from patients with a diagnosis of pancreatic adenocarcinoma for evaluation of circulating biomarkers.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-02-10
• Study First Submitted QC: 2023-02-22
• Study First Posted: 2023-02-24
• Study Start: 2023-02-27
• Status Verified: 2025-03
• Last Update Submitted: 2025-03-06
• Last Update Posted: 2025-03-10
• Primary Completion: 2027-06-30
• Study Completion: 2028-01-15

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• The subject must have a known or presumed diagnosis of pancreatic adenocarcinoma
• The subject must be a patient of the University of Pennsylvania
• The subject must be able to provide informed consent
• The subject must be 18 years of age or older

Exclusion Criteria

. Subjects who have any clinically significant psychiatric, social, or medical condition that, in the opinion of the investigator, could increase the patient's risk, interfere with protocol adherence, or affect the patient's ability to give informed consent are ineligible to participate in the study.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To create a comprehensive system to collect, catalogue and store blood specimens from subjects with pancreatic cancer for future research use.	Through study completion, an average of 1 year

Secondary Outcome Measures

Name	Time	Method
To create a computerized clinical data set from subjects with pancreatic cancer that contains information related to the subject's general health, disease status, treatments, and response.	Through study completion, an average of 1 year
To integrate the data and specimens to permit the most informative clinical-biologic research platform.	Through study completion, an average of 1 year

Trial Locations

Locations (1)

Abramson Cancer Center at University of Pennsylvania; 🇺🇸 Philadelphia, Pennsylvania, United States